Advertisement

Topics

Latest Drug Approvals NewsRSS

17:51 EST 9th December 2018 | BioPortfolio

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027 [Report Updated: 18072018] Prices from USD $9346

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027SummaryAmyotrophic Lateral Sclerosis ALS is a motor neuron degenerative disease which affects both upper motor neurons UMN and lower motor neurons LMN. It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split ...

1947 SILVER THREEPENCE PREDECIMAL COIN NICE AVERAGE CIRCULATED #VWR80

AU $3.00End Date: Tuesday Dec-25-2018 9:10:57 ESTBuy It Now for only: AU $3.00Buy It Now | Add to watch list Biotech365 : 1947 SILVER THREEPENCE PREDECIMAL COIN NICE AVERAGE CIRCULATED #VWR80 BioMarketplace You want to propose your products or a … Continue reading →

MIT Engineers Repurpose Wasp Venom as an Antibiotic Drug

NewsAltered peptides from a South American wasp's venom can kill bacteria but are nontoxic to human cells.Contributed Author: 

Opinion: Patent abuse by drug makers is one of the most influential drivers of rising drug prices. https://buff.ly/2L1VEpe 

Opinion: Patent abuse by drug makers is one of the most influential drivers of rising drug prices. https://buff.ly/2L1VEpe 

Report: U.S. Health Spending Hits $3.5T but Growth Slows

NewsThe report found a minimal increase in prescription drug spending, the slowest increase in drug costs since 2012.Contributed Author: 

Astellas gets FDA green light for Xospata

FDA partners with WHO to expedite review of HIV drug applications

STAT Plus: Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

Newly empowered Democrats in D.C. are hunting for bigger and bolder ways to lower drug prices and taking aim at the patents held by drug makers.

Surgeon General: Federal Drug Classification Needs Changes

NewsResearchers are having difficulty studying the medical potential of marijuana because of the drug's classification.Contributed Author:

Roche's Tecentriq gets first-line lung cancer approval

While a positive step for Roche's I/O ambitions, it will likely run into trouble differentiating Tecentriq from the first-line regimen of Keytruda plus chemo.

Opinion: Patent abuse is driving up drug prices. Just look at Lantus

Patent abuse is forcing agonized patients to struggle to afford treatment, ration their medicines, and absorb the cost of high drug prices with bodies.

Glenmark gains FDA approval for MS and pneumonia generics

In November 2018, Indian generics maker Glenmark Pharmaceuticals (Glenmark) announced the approval of generics for the treatment of multiple sclerosis (MS) and pneumonia.

NICE must provide patient decision aids if the tools are to become part of routine practice

In the National Institute for Health and Care Excellence’s (NICE) guideline NG5 — ‘Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes’ — sit recommendations around patient decision aids (PDAs) used in consultations involving ...

AEON Global Health Announces Adjournment of Annual Meeting of Shareholders until January 16, 2019

Annual Meeting adjourned solely with respect to Proposal 4 – approval of an amendment to the Company’s Amended Certificate of Incorporation to continue to restrict certain transfers of its common stock in order to preserve the tax treatment of its … Continue reading →

Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC

Late Thursday Genentech said the U.S. Food and Drug Administration (FDA) granted regulatory approval for a combination of Tecentriq and Avastin for treatment of some metastatic non-squamous non-small cell lung cancer (NSCLC) patient.

Roche's lung cancer combo treatment wins FDA approval https://reut.rs/2RAIPol 

Roche's lung cancer combo treatment wins FDA approval https://reut.rs/2RAIPol 

Twenty four gene fusions in one drug approval

FDA: ‘Rare but serious’ risk of stroke with MS drug alemtuzumab

The FDA is amending its label for alemtuzumab, a drug used to treat multiple sclerosis (MS) and leukemia, after 13 patients reported cases of ischemic stroke, hemorrhagic stroke or arterial dissection related to use of the medication.

HHS names new senior advisor for drug pricing reform

John O’Brien has been named as senior advisor to HHS Secretary Alex Azar for drug pricing reform, the agency announced Dec. 6.

Elbit Medical Technologies (EMTC) - Another FDA approval and a US IPO

Edison Investment Research - Pharmaceutical & healthcare - Elbit Medical Technologies: Elbit Medical Technologies’ two portfolio investments continue to advance. Notably, Gamida Cell announced a $53m IPO on Nasdaq in late October and presented NiCord data at the American Society of Hematology (ASH) annual meeting in December. InSightec reported record revenues for Q318 and received FDA appro...

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin and Kyowa Kirin International today announced that Crysvita™ (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of a...

STAT Plus: Supreme Court to decide a patent case with big implications for small drug makers

A ruling could chill deals that small drug makers may pursue in hopes of finding larger partners to get their medicines to market.

Worse Than Useless

Time for another look at AbbVie’s work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn’t look good. Now they look even worse. A Phase III trial of the drug has been

$RARE and Kyowa Kirin Announce Health Canada Approval of Crysvita™ for the Treatment of XLH in Adults and Children https://globenewswire.com/news-release/2018/12/06/1663089/0/en/Ultragenyx-and-Kyowa-Kirin-Announce-Health-Canada-Approval-of-Crysvita-buro

$RARE and Kyowa Kirin Announce Health Canada Approval of Crysvita™ for the Treatment of XLH in Adults and Children https://globenewswire.com/news-release/2018/12/06/1663089/0/en/Ultragenyx-and-Kyowa-Kirin-Announce-Health-Canada-Approval-of-Crysvita-burosumab-injection-for-the-Treatment-of-X-linked-Hypophosphatemia-XLH-in-Adults-and-Children.html …

Large spike in drug use-associated infective endocarditis linked with opioid epidemic

1. Researchers have identified a significant increase in hospitalizations due to infective endocarditis related to drug use. 2. Heart valve surgeries among patients with drug use-associated infective endocarditis have also increased with the opioid epidemic. Evidence Rating Level: 2 (Good) Study Rundown: The authors of this study utilized a statewide hospital discharge database to examine […...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Drug Approvals market research data and corporate reports here